Puma Bio - PBYI Company Cumulative Debt

Puma Biotechnology (PBYI) develops specialized solutions for breast cancer therapy. This business is insulated from economic fluctuations, as demand for treatment remains stable and success depends on the expansion of the drug Nerlynx. Historical price action for individual debt is 0.00. High service costs are justified by patents and proven efficacy, which guarantees support from insurance companies within this narrow niche.

Puma Biotechnology Inc - PBYI Company Debts (period 07/04/2022 - 10/27/2026)

Analytical breakdowns and data insights for company Puma Biotechnology (PBYI)

- price and consensus price forecast:

Price Performance Chart pumabiotechnology.com|PBYI - Analyst Consensus Forecast

- market capitalization data:

Market Value Puma Biotechnology Inc|PBYI - Enterprise Value

- book capitalization data:

Book Value per Share Puma Biotechnology|PBYI - Company Book Value|Market Capitalization to Book Value pumabiotechnology.com|PBYI - Cumulative Company Assets

- debt and liquidity data:

Aggregate Debt to Capital Puma Biotechnology|PBYI - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital pumabiotechnology.com|PBYI - Company Aggregate Debts|Debt to Book Value Puma Biotechnology Inc

Summary company analytics:PBYI Puma Bio

Original product of Puma Biotechnology, Inc.

Stable demand for HER2-positive breast cancer therapy directly impacts the aggregate debt dynamics of Puma Biotechnology (PBYI). This indicator aggregates all of the business's long-term bonds and bank loans. The total of these liabilities reflects the actual burden on the issuer's capital. Reducing the debt load minimizes default risks, although it may slow the pace of expansion. The current trend allows for a real-time assessment of the company's financial autonomy within a mature market.

Competing companies